Hemagglutinin–Neuraminidase of Human Parainfluenza 3: Role of the Neuraminidase in the Viral Life Cycle  by HUBERMAN, KETY et al.
VIROLOGY 214, 294–300 (1995)
SHORT COMMUNICATION
Hemagglutinin–Neuraminidase of Human Parainfluenza 3:
Role of the Neuraminidase in the Viral Life Cycle
KETY HUBERMAN,* RICHARD W. PELUSO,† and ANNE MOSCONA*,1
Departments of *Pediatrics and Cell Biology/Anatomy and †Microbiology, Mount Sinai School of Medicine,
1 Gustave L. Levy Place, New York, New York 10029-6574
Received August 21, 1995; accepted October 3, 1995
The function of neuraminidase in the life cycle and pathogenesis of human parainfluenza virus type 3 (HPF3) was studied
by analyzing a variant of HPF3 that has decreased neuraminidase enzymatic activity. The variant virus is more fusogenic
than the wild-type virus during an acute infection. Cloning and sequencing of the fusion (F) and hemagglutinin–neuraminidase
(HN) genes from this variant revealed a single amino acid change in the HN protein and no alterations in the F protein
sequence. Analysis of the growth properties of this variant revealed a delay in release of virus particles into the supernatant.
Addition of exogenous neuraminidase to the culture resulted in increased release of infectious viral particles, suggesting
that the viral neuraminidase is important for release of HPF3 from the infected cell surface. In addition, the behavior of the
variant virus during high-multiplicity infection and in the presence of exogenous neuraminidase provided evidence that the
neuraminidase of HPF3 determines the outcome of viral infection (cytopathic versus persistent) in cell culture. q 1995
Academic Press, Inc.
The envelope of human parainfluenza virus type 3 that the degree of cytopathology in an infected cell mono-
layer depends on the multiplicity of infection. During an(HPF3) contains two viral glycoproteins, the hemaggluti-
nin–neuraminidase (HN) and the fusion protein (F). HN acute, low-multiplicity infection with parainfluenza virus
type 3, virus spreads and mediates cell–cell fusion. Dur-binds to sialic acid-containing receptor molecules on the
target cell surface to initiate infection. F mediates fusion ing a high-multiplicity infection, sufficient sialic acid re-
ceptors are removed by the viral neuraminidase in theof the viral envelope with the cell membrane. Infection
inoculum to prevent cell fusion, but still allowing viralleads to fusion between cells and syncytium formation.
infection and spread, leading to persistent infection. WeWhile the F protein is critical for membrane fusion, we
showed that this phenomenon results from the neuramin-and others have found that the HN glycoprotein also
idase activity of the viral HN present in the inoculum.functions in cell fusion mediated by parainfluenza virus
The viral neuraminidase alters the host cell surface, mod-type 3 (1 – 3). Interaction of HN with its receptor is re-
ulating the number of available sialic acid receptors andquired in order for F to promote membrane fusion.
thus determining the outcome of infection. The fewerIn addition to its functions in receptor binding and
sialic acid receptors available to interact with other viralfusion promotion, the HN of HPF3, like that of other para-
HN molecules, the less opportunity for fusion to occur,myxoviruses, has neuraminidase activity that removes
and the more opportunity for persistent infection to de-sialic acid from receptor molecules. The role of this enzy-
velop (4).matic activity in the replicative cycle of HPF3 has not
To continue our study of the role played by the neur-been clear. Our previous studies led us to formulate a
aminidase in the life cycle and pathogenesis of HPF3,model for the role of the neuraminidase of HPF3 in de-
we isolated a variant of HPF3 (‘‘C-28’’) that has decreasedtermining the outcome of viral infection (4). We hypothe-
neuraminidase enzymatic activity relative to wt and havesized that neuraminidase activity of HN alters the host
used this variant to assess the functions of the neuramin-cell surface and determines the outcome of infection, by
idase in infection. Our findings about the role of the viralmodulating the quantity of receptor available to interact
neuraminidase in determining the outcome of infectionwith HN.
allowed us to make predictions about the behavior ofIn the experiments that led us to this model, we found
the low-neuraminidase variant. We could now test these
predictions using C-28, to build upon our understanding
of the complex interplay between the neuraminidase and1 To whom correspondence and reprint requests should be ad-
dressed. receptor-binding properties of HN during viral infection.
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FIG. 1. Fusion properties of low-neuraminidase HPF3 variants. Confluent cell monolayers were infected with either wt HPF3 or C-variant HPF3
at a m.o.i. of 0.01 PFU/cell. For observation of plaques, overlay medium was added after a 90-min adsorption period. The photographs show the
plaque size and morphology and the extent of CPE in a monolayer at 2 days after infection.
In addition, isolation of the low-neuraminidase variant C- The fusogenic variant has decreased neuraminidase
activity relative to wt HPF3. Figure 2 shows a time course28 allowed us to directly investigate which points in the
HPF3 viral life cycle require neuraminidase. of neuraminidase activity for wt and C28 over 180 min,
determined at pH 4.7 using the thiobarbituric acid assayHPF3 variants were isolated during growth of virus in
neuraminidase-treated cells (5) and were identified on (6) with a mixture of 2,3- and 2,6-neuraminyllactose as
substrate. For these experiments, sucrose gradient-puri-the basis of their ability to form large plaques in an un-
treated cell monolayer. Figure 1 shows the dramatic dif- fied virus was used. In each experiment, the released
neuraminic acid was quantitated only after standardiza-ference in plaque size and in cytopathic effect on a cell
monolayer between wild type and variant C-28. C-28 is tion of the input amounts of viral protein on stained,
scanned polyacrylamide gels, so that the amount of viralhighly fusogenic; plaques consisting of fused cells form
more rapidly and are much larger than wild-type plaques, protein used in the assay was the same for wt and C28.
At each time point, the activity of C28 is less than halfand infection of a monolayer results in more rapid and
widespread cell fusion. that of wt. In 24-hr assays of neuraminidase activity this
difference persisted; the activity of C28 at 24 hr rangedThe F and HN genes of C-28 were sequenced after
RT–PCR amplification of each gene, either by direct se- from 30 to 49% that of wt. Assays of the neuraminidase
activity of wt and C28 at 24 hr were repeated 20 separatequencing of the PCR product or by cloning into pUC19
and subsequent dideoxy sequencing of plasmid DNA (5). times, using different preparations of virus, and all indi-
vidual experiments were performed in triplicate.Sequence alterations were confirmed by repeating, at
least twice, the RNA isolation from infected cells, RT – The substrate specificity and pH optimum of the variant
are not significantly different from wt. Each neuramini-PCR amplification and sequencing of the altered region.
The variant has a wt F gene sequence and has one point dase has a greater than 10 to 1 preference for the 2-3
sialic acid linkage over the 2-6 linkage at pH 4.7, andmutation in the HN gene corresponding to a single amino
acid change in the HN glycoprotein. A G to A mutation each enzyme’s pH optimum is 4.7. For all experiments,
the pH in the reaction tube was checked at the start andat nucleotide 724 in variant C-28 converts aspartic acid
216 to an asparagine. This change does not create a end of the assay period to ensure that the correct pH
was maintained throughout.glycosylation site.
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role of neuraminidase in modulating the level of receptor
available to interact with HN and thus determining the
outcome of infection, we had made several predictions
about the behavior of a low-neuraminidase HPF3 variant.
These predictions were, first, that the variant would be
more fusogenic than wt; next, that the variant would be
capable of establishing persistent infection, but only at
a higher m.o.i. than that required by wt HPF3; and finally,
that establishment of persistent infection at low m.o.i.
could occur, but only after addition of more exogenous
neuraminidase than that required by wt. All three predic-
tions are fulfilled by C28. The variant fuses cells more
rapidly than wt (see Fig. 1), and the fusion is much more
widespread. C28 requires a multiplicity of infection of 10
in order to establish persistent infection, while wt HPF3
establishes persistent infection at a multiplicity of infec-
tion of 5. Finally, C28 requires the addition of 1 unit of
Clostridium perfringens neuraminidase in order to estab-
lish persistent infection, while wt HPF3 establishes per-
sistent infection after addition of 0.1 unit of neuramini-
FIG. 2. Neuraminidase activity of C28 variant compared to wt HPF3.
dase. Thus, this low-neuraminidase variant fits all theThe graph shows a time course of neuraminidase activity for wt and
predictions made by our model and provides further evi-C28 over 180 min. Neuraminidase activities were determined at pH
4.7, using a mixture of 2,3- and 2,6-neuraminyllactose as substrate. dence that neuraminidase determines the outcome of
Twenty-four-hour assay results are presented in the text. viral infection in culture.
We determined whether addition of exogenous neur-
aminidase alters the plaque phenotype (reflecting theThe rate of viral protein synthesis during infection was
determined by metabolic labeling of infected cells (7). fusion behavior) of the variant. We predicted that de-
creased neuraminidase activity of the variant would pro-Figure 3A shows that this rate was similar in wt- and
C28-infected cells at 3, 6, and 9 hr after infection. The mote increased membrane fusion through an increase
in available sialic acid receptors and that, conversely,major viral protein band, NP, has similar intensity in the
lanes corresponding to wild-type and C28-variant virus. decreasing the sialic acid receptors available to this virus
would block this increase in fusion. If this were true, thenIn addition, the relative amount of HN in wt- and variant-
infected cells is similar, determined by using densitomet- addition of exogenous neuraminidase should substitute
for the decrease in viral neuraminidase and should con-ric scanning to compare the relative densities of the
bands corresponding to HN and NP in each lane. vert the fusogenic C28 phenotype to a less fusogenic
phenotype. We tested this prediction by plaquing C-vari-Analysis of radiolabeled virus released from wt- and
C28-infected cells suggests that the incorporation of HN ant virus in the presence of varying amounts of C. per-
fringens neuraminidase in the agar overlay. At a concen-into particles is similar in the wt and variant viruses.
For preparation of radiolabeled viral particles, CV-1 cells tration of 0.05 units of neuraminidase per 3 million cells,
C-28 induced the formation of small, star-shaped plaqueswere infected with wt or variant virus for 24 hr in medium
containing one-tenth the normal amount of methionine that were indistinguishable from wt plaques. This pro-
vided additional evidence that the fusogenic phenotypeand [35S]methionine (20 mCi/ml). Figure 3B shows that
the relative amount of HN in wt and variant virus particles of C28 does indeed result from decreased viral neur-
aminidase.is similar, determined by comparing the relative densities
of the bands corresponding to HN and NP in each lane. The release of variant particles into the supernatant
was next assessed in order to determine whether theThe ability of C28 to bind to receptors on erythrocytes
was determined by performing HAD in variant- and wt- low-neuraminidase variant is delayed in release from the
cell surface. Figure 4 shows an analysis of the growthinfected cells and quantitating the relative numbers of
bound erythrocytes by lysing them and assaying hemo- properties of C-28 and wt viruses and reveals a delay in
release of C28 virus particles into the supernatant atglobin release (8). Virtually identical values were ob-
tained for C28 and wt, suggesting that the ability of C28 early times after infection. At 5 hr after infection, when
wt virus is already present in the supernatant, C28 hasto bind to sialic acid-containing receptors on erythrocytes
is not altered (data not shown). not yet begun to be released. Since C28 has lower neur-
aminidase activity, we tested whether exogenous neur-The low-neuraminidase variant behaves as predicted
by our model for neuraminidase action in determining aminidase could correct the delay in virus release. As
shown by the dashed line, the delay in release of C28the outcome of infection. Based upon our model of the
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FIG. 3. (A) The rate of viral protein synthesis in C-variant- and wt-infected cells. Monolayer cultures of CV-1 cells were infected with wt or C-
variant HPF3 at high m.o.i. (10 PFU/cell); these conditions of infection were chosen so that every cell would be infected at the time of the initial
inoculum and growth parameters would not be influenced by fusogenicity. The rate of viral protein synthesis was determined by metabolic labeling
of infected cells and was similar in wt- and C-variant-infected cells at 3, 6, and 9 hr after infection. The relative amount of HN in wt- and variant-
infected cells was determined by comparing the relative densities of the bands corresponding to HN and NP in each lane. (B) Analysis of the
amount of HN packaged into virus particles. Analysis of virus released from wt- and C28-infected cells shows that the ratio of HN to NP in wt and
variant virus particles collected at 24 hr after infection is similar, determined by comparing the relative densities of the bands corresponding to HN
and NP in each lane, suggesting that the incorporation of HN into particles is similar in the wt and variant viruses.
virus particles into the supernatant is corrected by adding virus could lead to an artificially low number of plaques
from the supernatant, if each aggregate resulted in onlyneuraminidase to the culture. For these experiments, 1
unit of C. perfringens neuraminidase was added to the one plaque. To test this, we neuraminidase-treated virus
released into the supernatant of C28-infected cells at 5infected cells (in 60-mm dishes) after the adsorption pe-
riod. These experiments were repeated with wt and C28 and 24 hr after infection, by incubating 1-ml aliquots of
supernatant fluid with 0.3 U of C. perfringens neuramini-a minimum of eight separate times for the standard
growth curves, and a minimum of four separate times dase, or without neuraminidase, for 60 min at 377. We
then determined the titer in plaque assays of this virus.with neuraminidase treatment. These results suggest
that the viral neuraminidase is important for release of The neuraminidase treatment did not increase the appar-
ent number of plaque-forming units in the culture super-virus from the cell surface.
We considered the possibility that the released virus natant, indicating that the variant virus does not undergo
self-aggregation once released into the culture super-particles that we detected after exogenous neuramini-
dase treatment might represent surviving particles from natant.
These studies begin to define the role of the neuramin-the inoculum that had failed to penetrate into cells, rather
than newly generated viruses. To test this, we performed idase enzymatic activity of HPF3 HN in the viral life cycle.
A single amino acid substitution in HN, resulting in de-parallel experiments in the presence of cycloheximide,
added to the cells at a concentration of 100 mg/ml after creased neuraminidase activity, promotes increased
membrane fusion through an increase in available sialicthe adsorption period. When protein synthesis was
blocked, the addition of neuraminidase did not release acid receptors. Since interaction of HN with its sialic acid
receptor is a critical first step in the fusion process, theviral particles from the infected cells, indicating that the
neuraminidase-induced release that we observed was presence of more available sialic acid receptors gives
HN more opportunity to interact with its receptor. This innewly produced virus (data not shown).
We determined whether the variant virus forms clumps turn may allow the F protein more time in which to induce
fusion.once released into the culture supernatant. Clumping of
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C28 HN is decreased, but not absent. Therefore, particles
are delayed in release at early times after infection, as
long as the total amount of viral neuraminidase is insuffi-
cient. As the infection progresses, since C28 retains
neuraminidase activity, neuraminidase in the culture
reaches a level at which viral particles can be efficiently
released from the cell surface. By 12 hr after infection in
these experiments, the neuraminidase level in the culture
of C28-infected cells has reached a level at which no
delay is present. After this time, release of particles is
similar to wt; the critical level of enzyme needed for this
function has been reached, and the number of particles
in the supernatant catches up to that in the wt infection.
The altered neuraminidase activity of C-28 HN results
from a single amino acid change in the HN glycoprotein;
aspartic acid 216 is an asparagine in the variant. The
aspartic acid at position 216 is absolutely conserved
among paramyxoviruses. The region of HN containing
FIG. 4. Growth characteristics of C28 compared to wt HPF3. The this amino acid has been found to be important for enzy-
release of variant particles into the supernatant was assessed to deter- matic activity in other paramyxoviruses (14–19). Colman
mine whether the low-neuraminidase variant is delayed in release from
et al. carried out a structural comparison between influ-the cell surface. Monolayer cultures of CV-1 cells were infected with
enza NA and several paramyxovirus HNs which led towt (open symbols) or C-variant (solid symbols) HPF3 at high m.o.i. (10
PFU/cell); these conditions of infection were chosen for reasons de- predictions about the three-dimensional structure and
tailed in the legend to Fig. 3A. The rate of viral replication was deter- potential functional sites on the paramyxovirus HN (20).
mined by plaque assay on virus released from infected cells and re- Based upon these comparisons, aspartic acid 216 in HN
veals a delay in release of C28 virus particles into the supernatant at
can be mapped onto the putative catalytic aspartic acidearly times after infection. As shown by the dashed line, the delay in
in influenza NA (21), corresponding to the absolutely con-release of C28 virus particles into the supernatant is corrected by
adding neuraminidase to the culture after the adsorption period. Stan- served NA residue 151 (NA sequence numbering corre-
dard errors and significance were calculated using the StatWorks soft- sponds to the N2 sequence). Thus, the aspartic acid 216
ware. *P  0.01; **P  0.05. to asparagine change we identified in C-28 HN alters
the amino acid predicted by this comparison to be the
catalytic aspartic acid. Our data argue against the abso-Studies on influenza A and B viruses have shown that
the neuraminidase protein (NA) is involved in release of lute requirement for participation of aspartic acid 216 in
catalysis, since an asparagine in this site in C28 de-newly assembled virus particles from the cell surface
and in prevention of self-aggregation (9–13). Recent creases but does not abolish enzymatic activity, and the
pH optimum of the enzyme is not altered.work using a NA-deficient influenza A virus mutant (10)
shows that the formation of aggregates of this virus at While paramyxoviruses have been considered to have
many biological properties in common with one another,the cell surface prevents virus from spreading to new
cells, thus inhibiting subsequent replication; entry, repli- several lines of investigation now point to the important
differences between viruses of this family in regard tocation, and assembly of the virus were not affected. In
contrast, for influenza B virus, studies of a ts mutant viral entry and fusion. The paramyxoviruses differ from
each other in the requirements for promotion of mem-defective in transport of NA to the cell surface (13) sug-
gest that NA is essential for assembly and/or budding brane fusion (2). Studies of a number of paramyxoviruses
have revealed that both the HN and the F proteins partici-of this virus. Our studies reported here show that for the
paramyxovirus HPF3, a significant (50–70%) reduction in pate in the fusion process; these include Sendai virus,
NDV, HPF2, mumps, measles, and canine distemper vi-neuraminidase activity does not hamper entry, replica-
tion, or assembly. Our data suggest that neuraminidase rus (reviewed in 22). However, it has been demonstrated
that for SV5, the F protein can mediate membrane fusionactivity is essential for release of newly assembled virus
particles from the cell surface. in the absence of HN and that coexpression of F and
HN has little effect on the degree of syncytium forma-The decreased neuraminidase activity of the HPF3 C28
variant delays release of virus particles from the cell tion (2, 23).
There are clearly differences between paramyxovi-surface. In addition to the known roles of the parainflu-
enza virus type 3 HN in receptor binding and fusion pro- ruses in the receptor requirements for virus entry and
spread. In one example, we have shown that HPF3 estab-motion, these findings implicate HN in release of virus
particles from the surface of the infected cell, to begin a lishes persistent infection, with no cell fusion at a m.o.i.
of 5; NDV, on the other hand, demonstrates widespreadnew round of infection. The neuraminidase activity of the
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cell fusion at the same m.o.i. and mediates fusion-from- that mumps and HPF3 may differ in their requirement for
neuraminidase in the release of particles from the cellwithout at higher m.o.i. (24). In comparing HPF3 to SV5,
we found that while at low m.o.i., the pathogenesis of surface. Studies with a temperature-sensitive mutant of
Sendai virus have shown that assembly into viral parti-HPF3 and SV5 are similar, in a high-m.o.i. infection the
manifestation of infection with each virus is strikingly cles can occur in the absence of HN protein (26), indicat-
ing that HN activity is not required for the assembly ordifferent (4). The fact that the fusion behavior of HPF3 and
SV5 are different at high m.o.i. supports the differences in budding processes for Sendai virus. It appears from past
studies in other paramyxoviruses that high levels of neur-observed fusogenic activity of the expressed F glycopro-
teins of these viruses. aminidase are not required for multicycle replication; for
example, a Newcastle disease virus (NDV) mutant whoseAnother important difference between viruses of this
family in regard to HN’s function in viral entry and fusion virions have only 3% of wt neuraminidase activity are still
infectious (27). It has been suggested that a thresholdbecomes apparent upon analysis of structure/function
relationships of the receptor-binding molecules. We have level of neuraminidase may be required for infectivity
(28); this threshold level may differ between paramyxovi-previously reported several HPF3 variants with amino
acid alterations in HN that increase avidity for receptor ruses.
There is a range of findings in the literature concerningand thus increase HN’s fusion promotion (5). One of
these, C-0, has a T193A change which promotes in- whether or not a relationship exists between neuramini-
dase activity and fusogenicity of paramyxoviruses, sug-creased binding of virus to receptor without altering neur-
aminidase activity, implicating the T193 region in the at- gesting another area of difference between individual
paramyxoviruses. Plaque variants of bovine parainflu-tachment process for HPF3. Interestingly, both mumps
(19) and NDV (14) variants altered in the residue corre- enza type 3 which exhibit altered fusion properties have
been isolated (29, 30), and the mutants with the leastsponding to T193 have decreased neuraminidase enzy-
matic activity. For NDV, the residue corresponding to 193 active neuraminidase were the most active in promoting
fusion and could be converted to the nonfusogenic phe-has been shown to influence both neuraminidase and
receptor recognition functions in a transient expression notype by exogenously added neuraminidase. Combina-
tions of the F and HN proteins coexpressed in cells dem-system (17) and a substitution at this site in bovine para-
influenza virus HN affects both functions as well (18). onstrated that the degree of cell fusion was dependent
on the type of HN protein coexpressed with F protein;Recently, the aspartic acid corresponding to HPF3’s
216 (the amino acid alteration in our C28 variant) has those with high NA activity exhibited less syncytium for-
mation (31). Additional evidence for the inverse relation-been altered in HN of NDV by site-specific mutagenesis,
in a transient expression system. (R. Iorio, personal com- ship of neuraminidase to F protein-mediated membrane
fusion comes from the study of mumps virus. The neur-munication.) In the resulting NDV HN, both neuramini-
dase activity and hemadsorption activity are severely im- aminidase activity of several naturally occurring strains
of mumps virus was compared, and those strains thatpaired. By contrast, a mutation of this residue in HPF3’s
HN resulted in a protein that retained significant hemads- exhibited high fusion activity possessed low levels of
neuraminidase, while those with high neuraminidase ac-orption activity, confirming our findings regarding recep-
tor-binding properties of the C-28 variant virus. These tivity were poorly fusogenic (32). For Sendai virus, studies
of plaque-size variants showed that neuraminidase activ-findings, while providing evidence for the importance of
this residue in paramyxovirus neuraminidase activity, ity did not correlate with plaque size (33). However, re-
cent studies using transient expression of the Sendaialso emphasize the difference between HPF3 and NDV
and highlight the emerging evidence that the paramyxovi- virus glycoproteins suggest that there may indeed be an
inverse relationship between neuraminidase activity andruses differ from each other in important ways in terms
of the function of their receptor-binding molecules. fusogenicity of Sendai virus (34). In contrast, studies us-
ing transiently expressed NDV glycoproteins suggestedIt also appears that there may be differences between
individual paramyxoviruses in their requirements for virus that the neuraminidase activity of HN did not correlate
with the fusion-promoting activity (35). For HPF3, ourparticle release from the cell surface. A mumps virus
variant with undetectable levels of neuraminidase activity work, presented here and in previous papers, favors the
hypothesis that the viral neuraminidase activity modu-(25) did not demonstrate a defect in multicycle replica-
tion, suggesting that release of virus particles was not lates the level of receptor available to interact with HN,
thus determining the degree of cell fusion. Clearly, thisseverely impaired. It is possible that the methods used
for detection of neuraminidase were not sensitive controversy points to another area of biologically im-
portant differences between these viruses.enough to detect a low level of activity and that the neur-
aminidase activity is not absent, but very low; still, that It would be valuable to investigate the behavior of the
variant C28 in an animal model. While the virus destroysvariant was not compromised in its growth properties.
While quantitative comparisons between that study and a cell monolayer more rapidly than wt HPF3 in cell cul-
ture, it is not clear whether this would translate into in-the present one are not possible, this difference suggests
/ m4484$7601 11-02-95 20:26:54 vira AP-Virology
300 SHORT COMMUNICATION
11. Palese, P., Tobita, K., Ueda, M., and Compans, R., Virology 61, 397–creased virulence in an animal. It has been proposed
410 (1974).that for influenza virus the neuraminidase activity may
12. Shibata, S., et al., J. Virol. 67, 3264–3273 (1993).
be important for removing respiratory tract mucin sialic 13. Yamamoto-Goshima, F., et al., J. Virol. 68, 1250–1254 (1994).
acids, thus lowering the mucin viscosity and allowing the 14. Iorio, R. M., Sydall, R. J., Glickman, R. L., Riel, A. M., Sheehan,
J. P., and Bratt, M. A., Virology 173, 196–204 (1989).virus to reach its target cell in the respiratory tract (36,
15. Iorio, R., and Glickman, R., J. Virol. 66, 6626–6633 (1992).37). While recent work using a neuraminidase-deficient
16. Lyn, D., Mazanec, M., Nedrud, J., and Portner, A., J. Gen. Virol. 72,influenza mutant (10) shows that neuraminidase function
817–824 (1991).
is not absolutely required for replication in the respiratory 17. Sheehan, J., and Iorio, R., Virology 189, 778–781 (1992).
tract of mice, it is possible that such a mechanism contri- 18. Shioda, T., Wakao, S., Suzu, S., and Shibuta, H., Virology 162, 388–
396 (1988).butes to pathogenesis. It is therefore possible that C28
19. Waxham, M. N., and Aronowski, J., Virology 167, 226–232 (1988).might be less virulent than wt HPF3 for several reasons;
20. Colman, P. M., Hoyne, P. A., and Lawrence, M. C., J. Virol. 67, 2972–in addition to the above possibility, the delay in release
2980 (1993).
of C28 virus particles might act to prevent virus from 21. Varghese, J., McKimm-Breschkin, J., Caldwell, J., Kortt, A., and Col-
spreading to new cells in the lung, thus inhibiting subse- man, P., Proteins Struct. Funct. Genet. 14, 327–332 (1992).
22. Lamb, R., Virology 197, 1–11 (1993).quent replication and severe disease.
23. Paterson, R. G., Hiebert, S. W., and Lamb, R. A., Proc. Natl. Acad.
Sci. USA 82, 7520–7524 (1985).ACKNOWLEDGMENTS
24. Bratt, M., and Gallaher, W., Proc. Natl. Acad. Sci. USA 64, 536–543
(1969).We thank Kurt Hirschhorn for continuing support and encouragement
and Ron Iorio for sharing data prior to publication. These studies were 25. Waxham, M. N., and Wolinsky, J. S., Virology 151, 286–295 (1986).
26. Stricker, R., and Roux, L., J. Gen. Virol. 72, 1703–1707 (1991).supported by Public Health Service Grants AI-31971 (A.M.) and AI-
22116 (R.W.P.) from the National Institutes of Health, and by an Irma 27. Smith, G., and Hightower, L., J. Virol. 47, 385–391 (1983).
28. Peeples, M., Glickman, R., Gallagher, J., and Bratt, M., Virology 164,T. Hirschl Career Scientist Award (A.M.). We are grateful to the Mount
Sinai Children’s Center Foundation for generous support. 284–289 (1988).
29. Shibuta, H., Nozawa, A., Shioda, T., and Kanda, T., Infect. Immun.
41, 780–788 (1983).REFERENCES
30. Shibuta, H., Kanda, T., Hazama, A., Adachi, A., and Matumoto, M.,
Infect. Immun. 34, 262–267 (1981).1. Hu, X., Ray, R., and Compans, R. W., J. Virol. 66, 1528–1534 (1992).
2. Horvath, C. M., Paterson, R. G., Shaughnessy, M. A., Wood, R., and 31. Sakai, Y., and Shibuta, H., J. Virol. 63, 3661–3668 (1989).
32. Merz, D. C., and Wolinsky, J. S., Virology 114, 218–227 (1981).Lamb, R. A., J. Virol. 66, 4564–4569 (1992).
3. Moscona, A., and Peluso, R. W., J. Virol. 65, 2773–2777 (1991). 33. Gorman, W., Takahashi, T., Scroggs, R., and Portner, A., Virology
180, 803–806 (1991).4. Moscona, A., and Peluso, R. W., J. Virol. 66, 6280–6287 (1992).
5. Moscona, A., and Peluso, R. W., J. Virol. 67, 6463–6468 (1993). 34. Bousse, T., Takimoto, T., Gorman, W., Takahashi, T., and Portner,
A., Virology 204, 506–514 (1994).6. Merz, D., Prehm, P., Scheid, A., and Choppin, P. W., Virology 112,
296–305 (1981). 35. Sergel, T., McGinnes, L., and Morrison, T., Virology 196, 831–834
(1993).7. Moscona, A., and Galinski, M. S., J. Virol. 64, 3212–3218 (1990).
8. Morrison, T., and McGinnes, L., Virology 171, 10–17 (1989). 36. Burnet, F., and Stone, J., Aust. J. Exp. Biol. Med. Sci. 25, 227–233
(1947).9. Liu, C., and Air, G., Virology 194, 403–407 (1993).
10. Liu, C., Eichelberger, M., Compans, R., and Air, G., J. Virol. 69, 37. Colman, P., and Ward, C., Curr. Top. Microbiol. Immunol. 114, 178–
254 (1985).1099–1106 (1995).
/ m4484$7601 11-02-95 20:26:54 vira AP-Virology
